Oncology – Gastrointestinal
Multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer.
24 Mar, 2022 | 08:45h | UTC
M-A: Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy in BRCA1/2 pathogenic variant (PV) carriers.
22 Mar, 2022 | 07:58h | UTC
Risk of colorectal cancer is associated with lifetime excess weight.
18 Mar, 2022 | 08:07h | UTCRisk of Colorectal Cancer Associated With Lifetime Excess Weight – JAMA Oncology
Diagnostic approach to incidentally detected pancreatic cystic lesions.
18 Mar, 2022 | 08:11h | UTCRelated:
Cystic pancreatic lesions: MR imaging findings and management.
Recommendations for the management of incidental pancreatic findings in adults.
Pancreatic cystic neoplasms: a review of current recommendations for surveillance and management
Management of Pancreatic Cystic Lesions
Consensus Recommendations: Diagnosis and Surveillance of Incidental Pancreatic Cystic Lesions
Review: Pancreatic Cystic Lesions
Guidelines on pancreatic cystic neoplasms
RCT: Short-term radiotherapy plus chemotherapy vs. long-term chemoradiotherapy in locally advanced rectal cancer.
18 Mar, 2022 | 07:39h | UTC
RCT: Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma.
17 Mar, 2022 | 08:07h | UTC
Commentary on Twitter
Phase III JUPITER-03 trial testing addition of the anti-PD-1 mAb toripalimab to first-line chemotherapy for advanced-stage ESCC, mPFS was 5.7 vs 5.5 months, although 1-year PFS was 27.8% vs 6.1% (HR 0.58) and mOS was 17 vs 11 months (HR 0.58): https://t.co/jNSVzNiAzR #esocsm
— NatureRevClinOncol (@NatRevClinOncol) March 10, 2022
RCT: In women undergoing cytoreductive surgery for ovarian cancer, the addition of hyperthermic intraperitoneal chemotherapy did not improve progression-free and overall survival.
16 Mar, 2022 | 09:41h | UTCRelated:
M-A: Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer.
RCT: Cytoreductive surgery for relapsed ovarian cancer.
A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer.
16 Mar, 2022 | 08:37h | UTC
Systematic review and non-inferiority meta-analysis of randomized phase II/III trials on S-1-based therapy vs. 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer.
15 Mar, 2022 | 08:06h | UTC
Mutational signatures and processes in hepatobiliary cancers.
14 Mar, 2022 | 00:43h | UTCMutational signatures and processes in hepatobiliary cancers – Nature Reviews Gastroenterology & Hepatology (if the link is paywalled, try this one)
Commentary on Twitter
Appeared online this week in @NatRevGastroHep ?
"Mutational signatures and processes in hepatobiliary cancers" a #Review article
Read here ??https://t.co/fUcaZ81BSA
Attached Figure: a clinicopathological and molecular overview of hepatobiliary cancers pic.twitter.com/d6MVAFu0J1— Nature Reviews Gastroenterology & Hepatology (@NatRevGastroHep) March 11, 2022
Feasibility of discharge within 72 hours of major colorectal surgery: lessons learned after 5 years of institutional experience with the ERAS protocol.
10 Mar, 2022 | 10:21h | UTCRelated:
ERAS Guidelines for Perioperative Care in Elective Colorectal Surgery
Review: Enhanced Recovery After Surgery in Emergency Colorectal Surgery
Commentary on Twitter
A five year #retrospective #cohort study explored link between early post-op discharge and #ERAS (n=965)
-> adherence to >80% ERAS components associated with early discharge. Long operations, drains, and complications assoc w/longer stays.https://t.co/2nXBrKbg5D#SoMe4Surgery pic.twitter.com/h5P4YFC8zh
— BJS Open (@BjsOpen) March 2, 2022
RCT: S-1 plus Oxaliplatin is non-inferior to Fluorouracil, Leucovorin plus Oxaliplatin as perioperative chemotherapy for locally advanced, resectable gastric cancer.
9 Mar, 2022 | 08:43h | UTC
Commentary on Twitter
In this RCT, S-1 plus oxaliplatin was noninferior to fluorouracil, leucovorin plus oxaliplatin as perioperative chemotherapy regimen for patients with locally advanced gastric cancer. https://t.co/W6fc1YcSBd
— JAMA Network Open (@JAMANetworkOpen) February 28, 2022
M-A: Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma.
7 Mar, 2022 | 00:07h | UTC
Commentary from the author on Twitter (thread – click for more)
In this global study of NAFLD-related HCC, we determine:
1.Prevalence
2.Clinical characteristics
3.% cirrhosis
4.Surveillance
5.Treatment allocation
6.Outcomes#LiverCancerSIG #LivertwitterFree to read @TheLancetOncol https://t.co/vwAeicpWxq
1/n pic.twitter.com/gM1BHVSwXl
— Daniel Huang (@DrHuangDQ) March 4, 2022
Phase 2, open-label RCT: Stereotactic body radiotherapy plus pembrolizumab and trametinib vs. stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection.
4 Mar, 2022 | 08:34h | UTCStereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Cancer risks other than female breast and ovarian cancers associated with BRCA1 and BRCA2 pathogenic variants.
3 Mar, 2022 | 08:14h | UTCCancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants – Journal of Clinical Oncology
Commentary: Faulty BRCA genes linked to prostate and pancreatic cancers – University of Cambridge
New treatment strategies for advanced-stage gastrointestinal stromal tumors.
27 Feb, 2022 | 22:28h | UTCNew treatment strategies for advanced-stage gastrointestinal stromal tumours – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)
Commentary on Twitter
In a Review now live online, @LRberyllium, @HKhosroyani, Jason D. Kent & Michael Heinrich from the @GistLab at @OHSUKnight discuss 'New treatment strategies for advanced-stage gastrointestinal stromal tumours: https://t.co/pJ0cMuvUMG #scmsm #stcsm #esocsm #CRCSM pic.twitter.com/lMtjkAcJUZ
— NatureRevClinOncol (@NatRevClinOncol) February 25, 2022
Top advances in esophageal/gastroesophageal junction cancers in 2021.
25 Feb, 2022 | 11:01h | UTCTop advances in esophageal/gastroesophageal junction cancers in 2021 – Cancer
RCT: Arterial chemotherapy of oxaliplatin plus fluorouracil vs. sorafenib in advanced hepatocellular carcinoma.
25 Feb, 2022 | 10:53h | UTCArterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
FOHAIC-1 Trial: Arterial FOLFOX chemotherapy improved survival outcomes compared to sorafenib in advanced #HepatocellularCarcinoma ? https://t.co/coazeM6Tq5 #JCO #hpbcsm #LiverCancer #hccsm pic.twitter.com/QDWdSD4P7e
— Journal of Clinical Oncology (@JCO_ASCO) January 4, 2022
An evidence-based guideline for surveillance of patients after curative treatment for colon and rectal cancer.
25 Feb, 2022 | 10:59h | UTC
A review of mucinous cystic and intraductal neoplasms of the pancreatobiliary tract: recent advances.
24 Feb, 2022 | 09:59h | UTC
AGA Guideline on systemic therapy for hepatocellular carcinoma.
23 Feb, 2022 | 10:14h | UTCAGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma – Gastroenterology
RCT | Comparison of 3 Paclitaxel-based chemoradiotherapy regimens for patients with locally advanced esophageal squamous cell cancer.
22 Feb, 2022 | 08:19h | UTC
RCT: Two vs. three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced esophageal squamous cell carcinoma.
21 Feb, 2022 | 08:25h | UTCMulticenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma – British Journal of Cancer (link to abstract – read for free here)
Commentary on Twitter
Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma
Read for free: https://t.co/vXRAP29FRo#Chemotherapy #Cancer pic.twitter.com/D7KBifTFOS
— British Journal of Cancer (@BrJCancer) February 9, 2022
ASCRS Guidelines for the management of colon cancer.
17 Feb, 2022 | 08:49h | UTC
Commentary on Twitter
This #DCRJournal highlights CPG: Colon Cancer – see all in these visual abstracts: https://t.co/qGE9lqZiIc@JonVogel7 @a_bham18 @alexhawkinsmd @seanlangenfeld @ajthorsenL @ColonCancerDoc @AmyLightnerMD @ianmpaquette @KyleCologne @SamAtallahMD @debby_keller @SeanLangenfeld pic.twitter.com/xqLeCF0lGz
— DCRjournal (@DCRjournal) February 7, 2022
M-A: In patients undergoing colorectal surgery with pelvic dissection, removing urinary catheters on postoperative days 3–4 may provide a balance, minimizing the risk of urine retention (increased when taken too soon) and urinary tract infections (increased when taken too late).
15 Feb, 2022 | 09:45h | UTC